Protein Sciences, Vaxine deal

Vaxine made an unsolicited bid to acquire fellow vaccine company Protein Sciences in a stock deal that could exceed $60 million. Protein Sciences said it is reviewing the offer. The companies are already collaborating on a preclinical pandemic influenza vaccine and have submitted a bid in response to an RFP from HHS's Biomedical Advanced Research and Development Authority (BARDA). Protein Sciences' FluBlok trivalent influenza vaccine is under FDA Priority Review, with a PDUFA date in early 2009. Vaxine has vaccines in Phase II testing to prevent HBV and influenza. ...